Henk Mallo

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank, Elisa A. Rozeman, Lorenzo F. Fanchi et al. · Nature Medicine · 2018 · 833 citations

Medicine, Melanoma, Immunology +6

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 322 citations

Biomarker Analyses, Medicine, Melanoma +8

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Joost H. van den Berg, Bianca Heemskerk, Nienke van Rooij et al. · Journal for ImmunoTherapy of Cancer · 2020 · 184 citations · Full text

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Astrid A.M. van der Veldt, Epie Boven, Helgi H. Helgason et al. · British Journal of Cancer · 2008 · 130 citations · Full text

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska et al. · Annals of Oncology · 2023 · 112 citations · Full text

Skin Cancer, Medicine, Opacin-neo Trials +7